Dasher Neuroscience Completes Recruitment for YA-101 Phase 2 Trial
Dasher Neuroscience has completed recruitment of 90 patients for a global Phase 2 trial of YA-101 in multiple system atrophy. The company expects top line clinical data in the first quarter of 2027.